Monte Rosa Therapeutics, Inc.

NasdaqGS:GLUE Stock Report

Market Cap: US$1.1b

Monte Rosa Therapeutics Valuation

Is GLUE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of GLUE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: GLUE ($16.45) is trading below our estimate of fair value ($37.1)

Significantly Below Fair Value: GLUE is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for GLUE?

Key metric: As GLUE is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for GLUE. This is calculated by dividing GLUE's market cap by their current earnings.
What is GLUE's PE Ratio?
PE Ratio51.1x
EarningsUS$20.95m
Market CapUS$1.07b

Price to Earnings Ratio vs Peers

How does GLUE's PE Ratio compare to its peers?

The above table shows the PE ratio for GLUE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average22.1x
KROS Keros Therapeutics
10x-45.19%US$646.8m
STOK Stoke Therapeutics
46.4x-21.08%US$1.9b
CVAC CureVac
7.4x4.25%US$1.1b
ALVO Alvotech
24.3x40.82%US$1.7b
GLUE Monte Rosa Therapeutics
51.1x-42.88%US$1.1b

Price-To-Earnings vs Peers: GLUE is expensive based on its Price-To-Earnings Ratio (51.1x) compared to the peer average (22.1x).

Price to Earnings Ratio vs Industry

How does GLUE's PE Ratio compare vs other companies in the US Biotechs Industry?

8 CompaniesPrice / EarningsEstimated GrowthMarket Cap
NVAX Novavax
3.1x-61.28%US$1.07b
ABEO Abeona Therapeutics
3.3x12.70%US$275.29m
CHRS Coherus Oncology
2.8x-10.24%US$168.01m
CARM Carisma Therapeutics
0.2xn/aUS$1.99m
GLUE 51.1xIndustry Avg. 18.8xNo. of Companies8PE01632486480+
8 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: GLUE is expensive based on its Price-To-Earnings Ratio (51.1x) compared to the US Biotechs industry average (18.8x).

Price to Earnings Ratio vs Fair Ratio

What is GLUE's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

GLUE PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio51.1x
Fair PE Ratio10.8x

Price-To-Earnings vs Fair Ratio: GLUE is expensive based on its Price-To-Earnings Ratio (51.1x) compared to the estimated Fair Price-To-Earnings Ratio (10.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst GLUE forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$16.45
US$17.20
+4.56%
14.43%US$20.00US$13.00n/a5
Dec ’26US$15.78
US$17.20
+9.00%
14.43%US$20.00US$13.00n/a5
Nov ’26US$12.85
US$15.50
+20.62%
22.89%US$20.00US$10.00n/a6
Oct ’26US$7.50
US$15.71
+109.52%
21.16%US$20.00US$10.00n/a7
Sep ’26US$4.80
US$15.29
+218.45%
20.30%US$20.00US$10.00n/a7
Aug ’26US$4.79
US$15.29
+219.12%
20.30%US$20.00US$10.00n/a7
Jul ’26US$4.61
US$15.29
+231.58%
20.30%US$20.00US$10.00n/a7
Jun ’26US$4.18
US$15.71
+275.94%
22.23%US$20.00US$10.00n/a7
May ’26US$4.90
US$16.13
+229.08%
21.36%US$20.00US$10.00n/a8
Apr ’26US$4.43
US$16.13
+264.00%
21.36%US$20.00US$10.00n/a8
Mar ’26US$5.50
US$16.00
+190.91%
18.30%US$20.00US$11.00n/a7
Feb ’26US$6.66
US$16.00
+140.24%
18.30%US$20.00US$11.00n/a7
Jan ’26US$6.94
US$16.00
+130.55%
18.30%US$20.00US$11.00n/a7
Dec ’25US$10.36
US$16.43
+58.58%
14.13%US$20.00US$14.00US$15.787
Nov ’25US$8.90
US$15.71
+76.57%
25.84%US$20.00US$7.00US$12.857
Oct ’25US$5.30
US$14.57
+174.93%
27.17%US$20.00US$7.00US$7.507
Sep ’25US$6.17
US$14.57
+136.17%
27.17%US$20.00US$7.00US$4.807
Aug ’25US$4.37
US$15.00
+243.25%
23.64%US$20.00US$9.00US$4.797
Jul ’25US$3.94
US$15.00
+280.71%
23.64%US$20.00US$9.00US$4.617
Jun ’25US$4.12
US$15.00
+264.08%
23.64%US$20.00US$9.00US$4.187
May ’25US$5.94
US$15.43
+159.74%
24.71%US$20.00US$9.00US$4.907
Apr ’25US$7.14
US$15.71
+120.09%
26.72%US$22.00US$9.00US$4.437
Mar ’25US$6.30
US$16.00
+153.97%
24.78%US$22.00US$10.00US$5.507
Feb ’25US$4.95
US$15.14
+205.92%
35.37%US$22.00US$5.00US$6.667
Jan ’25US$5.65
US$15.14
+168.02%
35.37%US$22.00US$5.00US$6.947
Dec ’24US$3.12
US$16.50
+428.85%
37.36%US$26.00US$5.00US$10.368
US$17.2
Fair Value
4.4% undervalued intrinsic discount
5
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/16 10:52
End of Day Share Price 2025/12/15 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Monte Rosa Therapeutics, Inc. is covered by 11 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Zhiqiang ShuBerenberg
Michael SchmidtGuggenheim Securities, LLC
Yuxi DongJefferies LLC